Schond L. Greenway net worth and biography

Schond Greenway Biography and Net Worth

Schond Greenway is the CFO of Definium Therapeutics.

What is Schond L. Greenway's net worth?: The estimated net worth of Schond L. Greenway is at least $3.76 million as of December 26th, 2023. Greenway owns 216,617 shares of Definium Therapeutics stock worth more than $3,758,305 as of February 10th. This net worth evaluation does not reflect any other assets that Greenway may own. Learn More about Schond L. Greenway's net worth.
How do I contact Schond L. Greenway?: The corporate mailing address for Greenway and other Definium Therapeutics executives is One World Trade Center Suite 8500 New York, NY 10007 United States. Definium Therapeutics can also be reached via phone at 212 220 6633 and via email at [email protected]. Learn More on Schond L. Greenway's contact information.
Has Schond L. Greenway been buying or selling shares of Definium Therapeutics?: Schond L. Greenway has not been actively trading shares of Definium Therapeutics during the past quarter. Most recently, Schond L. Greenway sold 5,652 shares of the business's stock in a transaction on Tuesday, December 26th. The shares were sold at an average price of $3.63, for a transaction totalling $20,516.76. Following the completion of the sale, the chief financial officer now directly owns 216,617 shares of the company's stock, valued at $786,319.71. Learn More on Schond L. Greenway's trading history.
Who are Definium Therapeutics' active insiders?: Definium Therapeutics' insider roster includes Robert Barrow (Chief Executive Officer and Board Director), Schond Greenway (CFO), David Gryska (Director), Dan Karlin (Insider), Daniel Karlin (Insider), Carrie Liao (CAO), and Mark Sullivan (Insider). Learn More on Definium Therapeutics' active insiders.
Are insiders buying or selling shares of Definium Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 163,667 shares worth more than $1,515,041.22. The most recent insider tranaction occured on December, 26th when insider Daniel Karlin sold 5,600 shares worth more than $73,640.00. Insiders at Definium Therapeutics own 2.3% of the company. Learn More about insider trades at Definium Therapeutics.
Information on this page was last updated on 12/26/2025.

Schond L. Greenway Insider Trading History at Definium Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/26/2023	Sell	5,652	$3.63	$20,516.76	216,617
9/25/2023	Sell	5,762	$3.58	$20,627.96	222,269
8/25/2023	Sell	20,000	$3.80	$76,000.00	228,031
6/27/2023	Sell	11,635	$3.20	$37,232.00	248,031

Schond L. Greenway Buying and Selling Activity at Definium Therapeutics

Definium Therapeutics Company Overview

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

Today's Range

Now: $17.35

$16.55

$17.40

50 Day Range

MA: $14.38

$11.94

$18.23

2 Week Range

Now: $17.35

$4.70

$18.70

Volume

829,525 shs

Average Volume

1,992,820 shs

Market Capitalization

$1.71 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57